BioLife Solutions Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
BioLife Solutions wird ein jährliches Gewinn- und Umsatzwachstum von 49.5% bzw. 17.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 49.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 2.9% betragen.
Wichtige Informationen
49.5%
Wachstumsrate der Gewinne
49.53%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 17.5% |
| Wachstumsrate der Einnahmen | 17.1% |
| Zukünftige Eigenkapitalrendite | 2.90% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 22 Apr 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
BLFS: New Biopreservation Center Will Support Stronger Margins And Future Returns
Analysts have nudged their price target for BioLife Solutions higher to align with a fair value estimate of about US$32.44 per share, up from roughly US$31.30. This adjustment reflects updated assumptions around slightly lower revenue growth, a modestly higher discount rate, stronger profit margins, and a somewhat lower future P/E multiple.BioLife Solutions: Back To Basics Is Getting Traction (Rating Upgrade)
Summary After multiple acquisitions and significant dilution of shareholders, BioLife shed two freezer businesses that it couldn't get going. Focusing mostly on its core biopreservation media business is putting BLFS on much sounder footing, as it generates the highest margins and the company has a competitive advantage. This is already paying off with cash flow steadily increasing. While the shares are not cheap, revenue growth is likely at 20%+ as more client therapies become commercial. Read the full article on Seeking AlphaBioLife Solutions, Inc.'s (NASDAQ:BLFS) P/S Is Still On The Mark Following 25% Share Price Bounce
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...Is BioLife Solutions (NASDAQ:BLFS) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Investors Still Waiting For A Pull Back In BioLife Solutions, Inc. (NASDAQ:BLFS)
When close to half the companies in the Life Sciences industry in the United States have price-to-sales ratios (or...Expanding Cell And Gene Therapy Workflows Will Shape Future Opportunities
Market leadership in cell and gene therapy, combined with expanded high-value product offerings, drives strong revenue and margin growth opportunities.An Intrinsic Calculation For BioLife Solutions, Inc. (NASDAQ:BLFS) Suggests It's 44% Undervalued
Key Insights BioLife Solutions' estimated fair value is US$44.43 based on 2 Stage Free Cash Flow to Equity BioLife...With BioLife Solutions, Inc. (NASDAQ:BLFS) It Looks Like You'll Get What You Pay For
When you see that almost half of the companies in the Life Sciences industry in the United States have price-to-sales...Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 27% after a shaky period...Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?
BioLife Solutions, Inc. ( NASDAQ:BLFS ), might not be a large cap stock, but it saw a significant share price rise of...Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results
BioLife Solutions, Inc. ( NASDAQ:BLFS ) investors will be delighted, with the company turning in some strong numbers...Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Key Insights BioLife Solutions' estimated fair value is US$31.49 based on 2 Stage Free Cash Flow to Equity BioLife...Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
BioLife Solutions, Inc. ( NASDAQ:BLFS ), is not the largest company out there, but it led the NASDAQCM gainers with a...Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders would be excited to see that the share price has had a great...BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, BioLife Solutions fair value estimate is US$24.10 BioLife...Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shares have had a really impressive month, gaining 25% after a shaky period...Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
BioLife Solutions, Inc. ( NASDAQ:BLFS ) shareholders will have a reason to smile today, with the analysts making...Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
While BioLife Solutions, Inc. ( NASDAQ:BLFS ) might not have the largest market cap around , it received a lot of...Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 162 | 43 | 23 | N/A | 2 |
| 12/31/2027 | 133 | 16 | 22 | 13 | 8 |
| 12/31/2026 | 113 | 6 | 13 | 4 | 10 |
| 12/31/2025 | 96 | -12 | 10 | 20 | N/A |
| 9/30/2025 | 100 | -18 | 10 | 17 | N/A |
| 6/30/2025 | 93 | -19 | 11 | 16 | N/A |
| 3/31/2025 | 88 | -9 | 9 | 15 | N/A |
| 12/31/2024 | 75 | -9 | 3 | 8 | N/A |
| 9/30/2024 | 53 | 2 | 2 | 9 | N/A |
| 6/30/2024 | 56 | -13 | -8 | 0 | N/A |
| 3/31/2024 | 65 | -13 | -22 | -14 | N/A |
| 12/31/2023 | 68 | -12 | -24 | -12 | N/A |
| 9/30/2023 | 126 | -79 | -22 | -7 | N/A |
| 6/30/2023 | 143 | -74 | -17 | -1 | N/A |
| 3/31/2023 | 155 | -141 | -19 | -3 | N/A |
| 12/31/2022 | 76 | 0 | -22 | -8 | N/A |
| 9/30/2022 | 155 | -106 | -28 | -17 | N/A |
| 6/30/2022 | 148 | -96 | -27 | -17 | N/A |
| 3/31/2022 | 139 | -15 | -27 | -14 | N/A |
| 12/31/2021 | 119 | -9 | -19 | -5 | N/A |
| 9/30/2021 | 97 | 5 | -19 | -2 | N/A |
| 6/30/2021 | 74 | 4 | -19 | -4 | N/A |
| 3/31/2021 | 53 | -20 | -3 | 8 | N/A |
| 12/31/2020 | 48 | 2 | -1 | 7 | N/A |
| 9/30/2020 | 42 | 7 | 0 | 3 | N/A |
| 6/30/2020 | 37 | 16 | 1 | 5 | N/A |
| 3/31/2020 | 34 | 39 | -3 | 1 | N/A |
| 12/31/2019 | 27 | -2 | -1 | 1 | N/A |
| 9/30/2019 | 25 | -32 | N/A | 3 | N/A |
| 6/30/2019 | 23 | -39 | N/A | 2 | N/A |
| 3/31/2019 | 22 | -44 | N/A | 3 | N/A |
| 12/31/2018 | 20 | -25 | N/A | 2 | N/A |
| 9/30/2018 | 17 | 1 | N/A | 3 | N/A |
| 6/30/2018 | 15 | 0 | N/A | 2 | N/A |
| 3/31/2018 | 12 | -2 | N/A | 1 | N/A |
| 12/31/2017 | 11 | -3 | N/A | 1 | N/A |
| 9/30/2017 | 10 | -5 | N/A | -1 | N/A |
| 6/30/2017 | 9 | -6 | N/A | -2 | N/A |
| 3/31/2017 | 9 | -7 | N/A | -3 | N/A |
| 12/31/2016 | 8 | -7 | N/A | -4 | N/A |
| 9/30/2016 | 8 | -5 | N/A | -5 | N/A |
| 6/30/2016 | 7 | -5 | N/A | -5 | N/A |
| 3/31/2016 | 7 | -4 | N/A | -5 | N/A |
| 12/31/2015 | 6 | -4 | N/A | -5 | N/A |
| 9/30/2015 | 6 | -4 | N/A | -4 | N/A |
| 6/30/2015 | 6 | -4 | N/A | -4 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: BLFS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.5%).
Ertrag vs. Markt: BLFS wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: BLFS wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: BLFSDie Einnahmen des Unternehmens (17.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.5% pro Jahr).
Hohe Wachstumseinnahmen: BLFSDie Einnahmen des Unternehmens (17.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: BLFSDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (2.9%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/07 22:38 |
| Aktienkurs zum Tagesende | 2026/05/07 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
BioLife Solutions, Inc. wird von 18 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Robert Wasserman | Benchmark Company |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| George Zavoico | B. Riley Securities, Inc. |